EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Nasopharyngeal Cancinoma (NPC) · Recurrent Nasopharynx Carcinoma · Metastatic Nasopharyngeal Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Contact: Study coordinator (Zhao Chong MD. PhD.) · zhaochong@sysucc.org.cn · 02087342638
Contact: Study coordinator (Miao Jingjing MD.) · miaojj@sysucc.org.cn · 86+13631355201

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC

Nasopharyngeal Cancinoma (NPC) · Nasopharangeal Cancer

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China · Shenzhen, China

LDRT and Chemoimmunotherapy in NPC With Liver Metastasis

Nasopharyngeal Cancinoma (NPC)

Abroad (travel likely)RecruitingPHASE2

Changsha, China · Changsha, China

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

Advanced or Metastatic Squamous Non-Small Cell Lung Cancer · Advanced Head and Neck Squamous Cell Carcinoma · Advanced Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Sydney, Australia · Westmead, Australia

Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy

Nasopharyngeal Cancinoma (NPC)

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China